Do analysts rate NNVC or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NNVC or SYBX more profitable?

Synlogic's return on equity of -26.47% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Synlogic N/A -26.47% -18.00%

Do analysts recommend VIRI or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VIRI or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Synlogic N/A -26.47% -18.00%

Do analysts rate SYBX or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 315.51%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SYBX or LSTA more profitable?

Synlogic's return on equity of -26.47% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Lisata Therapeutics N/A -103.54% -83.08%

Do analysts rate SYBX or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 649.03%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Do analysts recommend DARE or SYBX?

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 397.51%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Dare Bioscience is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or SYBX more profitable?

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Synlogic N/A -26.47% -18.00%

Synlogic (SYBX) Competitors

$0.79 +0.06 (+8.22%)

As of 03:36 PM Eastern

Compare

SYBX vs. NNVC, VIRI, LSTA, ALGS, and DARE

Should you buy Synlogic stock or one of its competitors? MarketBeat compares Synlogic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synlogic include NanoViricides (NNVC), Virios Therapeutics (VIRI), Lisata Therapeutics (LSTA), Aligos Therapeutics (ALGS), and Dare Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry.

How does Synlogic compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

NanoViricides has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Synlogic	$8K	1,155.08	-$23.36M	-$0.06	N/A

In the previous week, NanoViricides' average media sentiment score of 0.23 beat Synlogic's score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
Synlogic	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Synlogic's return on equity of -26.47% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Synlogic	N/A	-26.47%	-18.00%

Summary

NanoViricides beats Synlogic on 7 of the 12 factors compared between the two stocks.

How does Synlogic compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Synlogic	Neutral

Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Synlogic's return on equity of -26.47% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Synlogic	N/A	-26.47%	-18.00%

Virios Therapeutics has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Synlogic	$8K	1,155.08	-$23.36M	-$0.06	N/A

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 2.6% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Synlogic beats Virios Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Synlogic compare to Lisata Therapeutics?

Synlogic (NASDAQ:SYBX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 315.51%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Synlogic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Lisata Therapeutics had 5 more articles in the media than Synlogic. MarketBeat recorded 5 mentions for Lisata Therapeutics and 0 mentions for Synlogic. Lisata Therapeutics' average media sentiment score of 1.87 beat Synlogic's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Synlogic	Neutral
Lisata Therapeutics	Very Positive

Lisata Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,155.08	-$23.36M	-$0.06	N/A
Lisata Therapeutics	$170K	193.45	-$16.59M	-$1.86	N/A

Synlogic's return on equity of -26.47% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Summary

Lisata Therapeutics beats Synlogic on 9 of the 14 factors compared between the two stocks.

How does Synlogic compare to Aligos Therapeutics?

Synlogic (NASDAQ:SYBX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Synlogic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Synlogic has higher earnings, but lower revenue than Aligos Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,155.08	-$23.36M	-$0.06	N/A
Aligos Therapeutics	$2.19M	14.53	-$24.19M	-$8.69	N/A

In the previous week, Aligos Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Aligos Therapeutics and 0 mentions for Synlogic. Aligos Therapeutics' average media sentiment score of 0.94 beat Synlogic's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Synlogic	Neutral
Aligos Therapeutics	Positive

Aligos Therapeutics has a consensus target price of $38.50, indicating a potential upside of 649.03%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Synlogic has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Synlogic's return on equity of -26.47% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

63.4% of Synlogic shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aligos Therapeutics beats Synlogic on 10 of the 17 factors compared between the two stocks.

How does Synlogic compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Dare Bioscience had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Dare Bioscience and 0 mentions for Synlogic. Dare Bioscience's average media sentiment score of 0.94 beat Synlogic's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Positive
Synlogic	Neutral

Dare Bioscience has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 397.51%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities analysts plainly believe Dare Bioscience is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Synlogic	N/A	-26.47%	-18.00%

Dare Bioscience has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	29.23	-$13.40M	-$0.95	N/A
Synlogic	$8K	1,155.08	-$23.36M	-$0.06	N/A

Summary

Dare Bioscience beats Synlogic on 11 of the 15 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.24M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-3.04	19.00	24.49	23.62
Price / Sales	1,155.08	290.52	500.93	104.92
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.72	8.00	10.43	6.71
Net Income	-$23.36M	$23.89M	$3.56B	$337.26M
7 Day Performance	12.86%	-3.48%	-1.37%	-1.39%
1 Month Performance	22.48%	1.04%	0.87%	1.17%
1 Year Performance	-38.04%	34.40%	19.41%	22.63%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	N/A	$0.79 +8.2%	N/A	-42.3%	$9.24M	$8K	N/A	80
NNVC NanoViricides	0.3919 of 5 stars	$1.51 -5.0%	N/A	-7.9%	$32.69M	N/A	N/A	20	Gap Down
VIRI Virios Therapeutics	N/A	$1.67 -1.8%	N/A	-70.1%	$32.16M	N/A	N/A	5	Gap Up
LSTA Lisata Therapeutics	2.6395 of 5 stars	$3.50 +0.6%	$15.00 +328.6%	+31.6%	$31.87M	$170K	N/A	30	News Coverage Positive News Gap Up
ALGS Aligos Therapeutics	3.3642 of 5 stars	$5.14 -2.1%	$38.50 +649.0%	-28.5%	$31.82M	$2.19M	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. NNVC, VIRI, LSTA, ALGS, and DARE

How does Synlogic compare to NanoViricides?

Summary

How does Synlogic compare to Virios Therapeutics?

Summary

How does Synlogic compare to Lisata Therapeutics?

Summary

How does Synlogic compare to Aligos Therapeutics?

Summary

How does Synlogic compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. NNVC, VIRI, LSTA, ALGS, and DARE

How does Synlogic compare to NanoViricides?

Which has more risk and volatility, NNVC or SYBX?

Which has higher earnings and valuation, NNVC or SYBX?

Does the media prefer NNVC or SYBX?

Do analysts rate NNVC or SYBX?

Do institutionals & insiders hold more shares of NNVC or SYBX?

Is NNVC or SYBX more profitable?

Summary

How does Synlogic compare to Virios Therapeutics?

Do analysts recommend VIRI or SYBX?

Does the media prefer VIRI or SYBX?

Which has more volatility & risk, VIRI or SYBX?

Is VIRI or SYBX more profitable?

Which has higher valuation and earnings, VIRI or SYBX?

Do institutionals & insiders have more ownership in VIRI or SYBX?

Summary

How does Synlogic compare to Lisata Therapeutics?

Do analysts rate SYBX or LSTA?

Which has more volatility & risk, SYBX or LSTA?

Do institutionals and insiders have more ownership in SYBX or LSTA?

Does the media refer more to SYBX or LSTA?

Which has higher earnings and valuation, SYBX or LSTA?

Is SYBX or LSTA more profitable?

Summary

How does Synlogic compare to Aligos Therapeutics?

Which has more risk and volatility, SYBX or ALGS?

Which has better valuation and earnings, SYBX or ALGS?

Does the media favor SYBX or ALGS?

Do analysts rate SYBX or ALGS?

Is SYBX or ALGS more profitable?

Do institutionals & insiders believe in SYBX or ALGS?

Summary

How does Synlogic compare to Dare Bioscience?

Do insiders & institutionals believe in DARE or SYBX?

Does the media favor DARE or SYBX?

Which has more risk and volatility, DARE or SYBX?

Do analysts recommend DARE or SYBX?

Is DARE or SYBX more profitable?

Which has higher valuation & earnings, DARE or SYBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools